EditorsAbout the SiteComes vs. MicrosoftUsing This Web SiteSite ArchivesCredibility IndexOOXMLOpenDocumentPatentsNovellNews DigestSite NewsRSS

10.30.10

When Life of a Patent is the Death of a Person

Posted in Patents at 5:30 pm by Dr. Roy Schestowitz

Life

Summary: News about controversial patents on genes, life-saving drugs, and TRIPS in ACTA

THIS post presents some news where patents are a matter of life and death.

US Government Argues in Court that Isolated Genes are Unpatentable (patents on genes were also covered in [1, 2])

In March, 2010, District Court Judge Robert Sweet held Myriad’s gene patent claims invalid for failing to satisfy the subject matter eligibility requirements of 35 U.S.C. 101. The ruling was directed toward claims that cover particular isolated DNA molecules (genes) and processes of detecting and screening for those genes, but was written broadly enough to essentially invalidate all patents covering genes that were isolated from an organism.

[...]

Thus, the patent laws embrace gene replacement therapies, engineered biologic drugs, methods of modifying the properties of plants or generating biofuels, and similar advanced applications of biotechnology. Crossing the threshold of section 101, however, requires something more than identifying and isolating what has always existed in nature, no matter how difficult or useful that discovery may be.

Big Pharma Stranglehold: Thwarting India As Independent Maker Of Blockbuster HIV Drugs? (“neocolonialism kills AIDS,” remarks Dr. Glyn Moody)

Until recently, the pharmaceutical giants were little interested in the developing world, while looking almost exclusively to the profitable United States and European markets. But now, their momentum is substantially slowing down there mainly due to stiff costs to renew product pipelines, generic competition, recent economic downturn and cost-conscious government and commercial payers. Additionally, over the next five years, drug companies will lose patent protection of products worth US$140 billion in yearly sales [1]. As a result, the brand industry is increasingly looking to the emerging markets of fast-growing middle-income countries (including India, China, Venezuela, Brazil, South Africa, South Korea, Indonesia, Colombia, Egypt, Vietnam and Turkey) where a number of well-off elites, who can afford out-of-pocket spending (about 300 million people in India, at least 800 million in China), now live. Expanding middle classes in such countries are not only spending more on healthcare, but their rising wealth is contributing to increased rates of chronic diseases once limited to the western markets. Without counting that, sales of prescription drugs are forecast to wane in the United States as an effect of new health-care legislation that could lower the price of medicines. This is adding pressure on drug makers’ US businesses.

[...]

Cheap brand and branded generics to rural India

Now that big pharma industry is pushing forward its breakthrough in India, the acquisitions of local firms, as just mentioned, have resulted in a multi-pronged, deeply profitable strategy wherein the impact of lower prices applied to end products is offset by taking advantage of the lower manufacturing, distribution and marketing costs in the country.

Until recently, the brand companies doing drug business in emerging economies have focused mostly on the wealthy and middle class. Now, they are turning also to the “bottom of the pyramid” and are conducting an exercise in how to cut prices down to seduce poorer customers and rural villagers in India while still turning a profit. To this aim, nearly all companies have boosted their sales forces (as an example, Abbott now employs approximately 10,000 people across all of its country businesses) [8]. Reportedly, these pitchmen are fanning out in rural India, where they train doctors and patients also hoping to capitalise on a $19.5 billion Indian public healthcare programme for 742 million villagers [10].

In short, the multinational companies are selling some branded treatments to Indian customers at lower-than-Western prices, while licensing cheap therapies from local firms (the so-called branded generics) to build portfolios of low-cost medicines [4]. Through the branded generics (90 percent of drug sales), the multinationals are deeply involved in the current rise of India’s pharmaceutical market [11]. It comes as no surprise that in countries where generic drugs may frequently be substandard or fake, selling generics under the brand of a leading enterprise can look to doctors and patients as a more trustworthy and reliable option. The branded generics market is generating nearly $8 billion in pharmaceutical sales this year, a figure that is expected to more than double by 2015 [11].

USTR positions in China WTO TRIPS dispute at odds with talking points on ACTA flexibility (“ACTA: Brazil, Ecuador and India made interventions on ACTA at WTO TRIPS Council,” summarises ThiruGeneva in this first part of Knowledge Ecology International coverage on ACTA in USTR, Brazil, and India)

In a dispute between the United States and Canada over the enforcement of intellectual property rights, Article 1.1 of the TRIPS played an important role. See: WTO DISPUTE DS362, China — Measures Affecting the Protection and Enforcement of Intellectual Property Rights.

In the US/China WTO dispute, the USTR took the position that parties have an obligation to “give effect to the provisions of the Agreement,” and that “Article 1.1 deals with the method by which a Member implements TRIPS Agreement obligations, not whether or to what extent a Member should implement them in the first place.”

One United States pleading in this dispute mentioned Article 1.1 of the TRIPS 15 times…

Brazilian intervention at TRIPS Council: ACTA

Extracts of India’s Intervention to the WTO TRIPS Council: ACTA (bricking BRIC)

On Wednesday, 27 October 2010, the WTO TRIPS Council held its annual review of the Paragraph 6 System. IP-Watch has a link to the detailed program of the annual review. This annual review of the Paragraph 6 system lasted till around 8 PM Geneva time. More details of this closed door meeting will be provided in due course. Sources close to the negotiations indicate that Canada provided a comprehensive overview of its implementation of the Paragraph 6 system, Canada’s Access to Medicines Regime (CAMR). Rwanda was not present at this review; neither was Ghana, a country which has tried unsuccessfully to make use of Paragraph 6. After 8 PM, the TRIPS Council resumed and certain Members took the floor to discuss ACTA. Here are some key extracts from the intervention made by India yesterday concerning ACTA.

TRIPS Council Discusses Efficacy Of ACTA, Public Health Amendment (for more on ACTA and TRIPS see this video which slams TRIPS [1, 2, 3, 4])

ACTA “completely bypasses the existing multilateral processes provided in particular by the WTO and WIPO” as well as providing for much higher level enforcement than called for under TRIPS, India said in prepared remarks. It is already doing so with a “startling” decision to overturn a decision of the WTO dispute settlement on a US-China dispute over counterfeiting and copyright piracy (IPW, WTO/TRIPS, 26 January 2010), India said. ACTA reinterprets the definition of “commercial scale” to mean “any activity carried out for a direct or indirect economic or commercial advantage” while the WTO recently determined that it meant a particular level of activity, the statement said.

As “ACTA members account for about 70% of world trade,” there is a risk the agreement will “undermine trade liberalisation when there already are several threats to the multilateral trading system in the form of trade protectionist measures in wake the of the economic crisis and a simmering currency issue,” India added. For this reason, India requested that “Enforcement Trends” be discussed at this TRIPS Council meeting, despite having a position in the past that enforcement should not be a permanent TRIPS agenda item, they said.

[...]

A WTO source said ACTA parties largely argued the agreement “does not affect TRIPS and that action is needed to tackle the real dangers arising from counterfeit products such as medicines and spare parts.”

Drugs counterfeiting prevention has had ACTA misused to push for draconian copyright law, under the guise of saving lives.

Share this post: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Reddit
  • co.mments
  • DZone
  • email
  • Google Bookmarks
  • LinkedIn
  • NewsVine
  • Print
  • Technorati
  • TwitThis
  • Facebook

If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

Pages that cross-reference this one

What Else is New


  1. Alice Continues to Smash Software Patents So Patent Lawyers, Monopolists' Lobbyists Etc. Now Attack the Supreme Court for Doing This

    Corporate lobbyists and patent lawyers are trying to put Alice in the grave, for its impact on software patents is very profound and thus far almost unstoppable



  2. How to Salvage the EPO's Reputation: Create More Boards of Appeal in Europe and Abolish the Misguided UPC Fantasy

    A critical evaluation of what goes on at the European Patent Office (EPO), which is quickly descending down (and overall degrading) to the level of Chinese systems, along with the corruption, the abuses, and the low quality of patents



  3. Court of Appeals for the Federal Circuit (CAFC) Has Just Sided With Patent Trolls

    The notorious CAFC, which manifested software patents in the United States, has just given a gift to patent trolls that typically use software patents for extortion down in Texas



  4. Analyses of the Latest Data From Lex Machina About Patent Litigation Show Some Litigation Declines

    Professor Mark Lemley's Lex Machina highlights litigation trends by collecting and analysing data related to patents and pertaining to intellectual monopolies in general; now it shows litigation droughts



  5. India is Having Another Taste of the Dangers of Western Patents, Must Learn to Reject Software Patents in the Face of Great Pressure

    The growing software giant which is India continues to face cruel and aggressive lobbying from the West, enabling the West to control India by patents that should not exist in the first place



  6. Links 29/4/2016: GNOME 3.21.1, Fairphone

    Links for the day



  7. Microsoft Says It Will Continue to Extort Companies That Distribute Linux, Using Software Patents As Usual

    Microsoft's war on Linux, a war which is waged using software patents (for revenue and/or for coercion in bundling deals), is still going on in spite of all the PR tactics from Microsoft and its paid partners



  8. Australia Might be Next to Block Software Patents If Commission's Advice is Followed

    Australian advice against software patents, which can hopefully influence Australian politicians and put an end, once and for all, to all software patents in Australia



  9. [ES] ''Si la Forma de Pensar de la EPO fuese Seguida, Guantánamo Sería Posible en Suelo Alemán.”

    La EPO está todavía bajo fuego, pero mucho de ello pasa detrás de las cortinas y envuelve abogados y/o burócratas



  10. The European Copy-Paste Office (EPO)

    This morning's example (not the first) of how the EPO uses 'social' media



  11. Links 28/4/2016: Fedora 24, EE Goes Open Source

    Links for the day



  12. Amid Referendum “the New European Unitary Patent System is Likely to Collapse Before It Started”

    The Unitary Patent Court (UPC) vision seems like it may be just one month away from its gradual death, depending on British voices amongst other key factors



  13. USTR is Trying to Shame and Bully India Into Introducing Software Patents in India

    Lobbying body of the US (corporations-led) is trying its usual dirty tactics against India's sound policy which excludes software/algorithms from patent scope



  14. No, Visual Studio is NOT Open Source and Xamarin Openwashing is NOT News

    The latest example of Microsoft openwashing, courtesy of confidants of Microsoft and those who got bamboozled by them



  15. Latest Black Duck Puff Pieces a Good Example of Bad Journalism and How Not to Report

    Why the latest "Future of Open Source Survey" -- much like its predecessors -- isn't really a survey but just another churnalism opportunity for the Microsoft-connected Black Duck, which is a proprietary parasite inside the FOSS community



  16. If EPO “Form of Thinking Were to be Followed, Guantanamo on German Soil Would be Possible.”

    The EPO is still under fire, but a lot of it happens behind the scenes and involves lawyers and/or bureaucrats



  17. Links 28/4/2016: Tomb Raider for GNU/Linux, Proxmox VE 4.2

    Links for the day



  18. [ES] La Departura de la Readidad de la EPO Y Su Entrada en la Esféra Industrial China de Propaganda

    La deceptiva trampa del maximálism de patentes, donde se asume que artficialmente aumentando el número de patentes otorgadas traerá el resultado esperado



  19. [ES] Una Fársa de Sistema: ¿Cómo la SIPO, USPTO, y cada vez más la EPO se Convierten en Llenado de Patentes (No Se Requiere Propia Examinación)

    Una crítica al decline en la calidad de patentes en algunas de las más grandes oficinas de patentes del mundo, donde aspiración parece ser neo-liberal en el sentido económico



  20. [ES] Microsoft ‘Asalto con Todo’ Contra Android, Java, y GNU/Linux, Usando la Clásica E.E.E. Táctica de Nuevo

    Otro recordatorio de la realidad que Microsoft está muy activo en el frente E.E.E., not no sólo contra GNU/Linux pero también Android y Java



  21. [ES] Más Rumores y Llamadas Acerca de Prospectos de Microsoft Vaya a Comprar Canonical (Ubuntu con todo y Zapatos)

    Teniendo en cuenta los últimos movimientos de Canonical, algunos expertos piensan que es posible que Shuttleworth elija el dinero a Microsoft sobre principios sino también inste para que esto ocurra



  22. Links 27/4/2016: A Lot About OpenStack, Vivaldi 1.1 Released

    Links for the day



  23. A Farce of a System: How SIPO, USPTO, and Increasingly the EPO Too Turn Into Filing Systems (No Proper Examination/Filtering Required)

    A critique of the declining quality of patents in some of the world's biggest patent offices, where the aspiration seems to be neo-liberal in the economic sense



  24. Microsoft's 'Full Assault' on Android, Java, and GNU/Linux, Using Classic E.E.E. Tactics Again

    Another reminder of the fact that Microsoft is very active on the E.E.E. front, not just against GNU/Linux but also Android and Java



  25. More Rumours and Calls Surrounding Prospects of Microsoft Buying Canonical (Ubuntu and More)

    Taking some of Canonical's recent moves into account, some pundits not only think it's possible for Shuttleworth to choose Microsoft money over principles but also urge for this to happen



  26. [ES] El Nuevo Impulso Finánciado por Microsoft Para Reforzar las Patentes de Software en los EE.UU., Apoyado por los Sospechosos Usuales (La Sagrada Familia) Mientras que Microsoft Cada Vez Más Lucha Como Compañíá Productiva

    Una mirada al esfuérzo de trae una resurgencia de las patentes de software en los Estados Unidos (con un clarísimo rol de Microsoft en él) y la fundación/conf ianza de Microsoften las patentes de software como arma contr Linux/Android porque las ganancias de Windows se están secando y el Windows Phone está al borde del colápso



  27. Links 26/4/2016: Firefox 46.0, Thunderbird's Stewardship

    Links for the day



  28. Links 25/4/2016: Kodi 16.1, OpenStack Summit

    Links for the day



  29. New Microsoft-Funded Push to Make Software Patents Stronger in the US, Backed by the Usual Suspects as Microsoft Increasingly Struggles as a Producing Company

    A look at the effort to bring about a software patents resurgence to the US (with clear Microsoft role in it) and Microsoft's reliance on software patents as a weapon against Linux/Android because Windows profits dry up and Windows Phone is on the verge of collapse



  30. Patents Roundup: Marijuana Patents, Patent Satellites, Patent Trolls, Wars, and Merchants (Notably Lawyers)

    Various strands of news about patents, focused on issues raised in the latter half of last week


CoPilotCo

RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

CoPilotCo

Recent Posts